216 related articles for article (PubMed ID: 11213012)
21. Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells.
McCarthy-Keith DM; Malik M; Britten J; Segars J; Catherino WH
Fertil Steril; 2011 Jun; 95(7):2383-7. PubMed ID: 21496801
[TBL] [Abstract][Full Text] [Related]
22. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
24. Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy.
Jasonni VM; D'Anna R; Mancuso A; Caruso C; Corrado F; Leonardi I
Acta Obstet Gynecol Scand; 2001 Oct; 80(10):956-8. PubMed ID: 11580742
[TBL] [Abstract][Full Text] [Related]
25. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
26. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
27. Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Huang SC; Tang MJ; Cheng YM; Hsu KF; Ho CL; Chou CY
J Clin Endocrinol Metab; 2003 Oct; 88(10):5009-16. PubMed ID: 14557488
[TBL] [Abstract][Full Text] [Related]
28. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
29. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
Hansen LM; Batzer FR; Corson SL; Bello S
J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
[TBL] [Abstract][Full Text] [Related]
30. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
31. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
Lethaby AE; Vollenhoven BJ
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
[TBL] [Abstract][Full Text] [Related]
32. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
33. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
34. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
[TBL] [Abstract][Full Text] [Related]
35. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
Lin Y; Kahn JA; Hillensjö T
Hum Reprod; 1999 Apr; 14(4):885-8. PubMed ID: 10221213
[TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells.
Chen W; Yoshida S; Ohara N; Matsuo H; Morizane M; Maruo T
J Clin Endocrinol Metab; 2005 Feb; 90(2):884-92. PubMed ID: 15536154
[TBL] [Abstract][Full Text] [Related]
37. Minimising menopausal side effects whilst treating endometriosis and fibroids.
Simpson PD; McLaren JS; Rymer J; Morris EP
Post Reprod Health; 2015 Mar; 21(1):16-23. PubMed ID: 25802141
[TBL] [Abstract][Full Text] [Related]
38. Medical management of fibroids.
Sankaran S; Manyonda IT
Best Pract Res Clin Obstet Gynaecol; 2008 Aug; 22(4):655-76. PubMed ID: 18468953
[TBL] [Abstract][Full Text] [Related]
39. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
40. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
